A computer model built from pure math can now simulate, step by step, how two metals in your brain help the sticky plaques of Alzheimer's form — and test future treatment ideas before anyone touches a lab bench.
Alzheimer's disease is driven partly by a protein called amyloid-beta that clumps together into sticky plaques inside the brain, and scientists have long suspected that metal ions like copper and zinc, which occur naturally in brain tissue, make that clumping worse. Shantia Yarahmadian, a mathematician at Mississippi State University, built a system of equations that simulates exactly how those metal ions interact with amyloid-beta over time, turning a messy biological process into something a computer can run over and over under different conditions. When he and his collaborators, Yasser Alzahrani and Vaghawan Prasad Ojha, compared what their equations predicted to real lab images of amyloid clumps taken with an atomic force microscope (a tool that "feels" a surface with an ultra-thin needle instead of using light), the model's predictions matched. That match means the same equations can now test two treatment ideas entirely inside a computer first: chelation therapy, which uses molecules that grab onto metal ions and pull them away, and drugs designed to block the clumping directly. The team is upfront that this doesn't prove either treatment works in a real patient — what it gives other researchers is a faster, cheaper way to rule out dead ends before anyone runs a slow, expensive lab experiment.
ScienceDaily, reporting Shantia Yarahmadian, Yasser Alzahrani & Vaghawan Prasad Ojha, Mississippi State University / Bulletin of Mathematical Biology · Oct 11, 2026 · sciencedaily.com
§
Why it's hereMost real math doesn't look like a flashy new theorem — it looks like this: a quiet simulation tool, built from equations instead of lab equipment, that could speed up the slow search for an Alzheimer's treatment without claiming to be a cure itself.
Physicists thought you needed to slam together the heaviest atoms on the periodic table to briefly recreate the universe's first instants. It turns out much smaller ones work too.
For a few millionths of a second after the Big Bang, the universe was filled with an extreme state of matter called quark-gluon plasma — hotter than anything that exists naturally today, with quarks and gluons (the particles that normally lock together inside protons) floating free instead of staying bound in place. At the Large Hadron Collider outside Geneva, physicists have spent years recreating tiny droplets of this plasma by smashing together lead nuclei, which are more than 200 times heavier than the protons used in most collisions, on the theory that more mass means more energy packed into a smaller space. But four separate detector teams there — known as ALICE, ATLAS, CMS, and LHCb — have now found convincing signs of that same extreme state of matter in collisions of much lighter oxygen and neon nuclei, something many physicists didn't expect. Each team used a different method to check: one measured how the plasma saps energy from fast-moving particles passing through it, another tracked how the number of particles produced gets suppressed compared to ordinary collisions, and others looked at how specific heavy particles behave differently depending on how the plasma "flows." Together, the results — estimated at temperatures over 100,000 times hotter than the center of the Sun — suggest that briefly recreating the universe's first instants doesn't take quite as much raw mass as physicists had assumed.
ScienceDaily, reporting the ALICE, ATLAS, CMS & LHCb Collaborations / CERN · Nov 2, 2026 · sciencedaily.com
§
Why it's hereIt's genuinely dizzying that humans can manufacture, on purpose, a tiny piece of what the entire universe looked like a fraction of a second after it began — and finding out it's easier to make than expected is a real, useful clue about how matter behaves at extremes, not just a cool party trick.
For a century, imaging the inside of cells has relied on a 1930s optical trick. Physicists just rebuilt that trick using one of the most powerful lasers ever focused into a single spot — for electrons instead of light.
Most of what's inside a living cell is water, which makes cells nearly transparent to ordinary light microscopes — proteins and other structures barely scatter any light, so they stay almost invisible unless you stain the cell, which kills it. In 1930, physicist Frits Zernike figured out a workaround called phase contrast: light passing through a cell gets slightly delayed even when it doesn't get dimmer, and shifting that delay by exactly 90 degrees makes invisible structures suddenly visible, a trick that won him a Nobel Prize in 1953. Electron microscopes, which magnify roughly 10,000 times more than light microscopes and are already used to map the 3D shape of proteins in a technique called cryo-EM, never had an equivalent trick, because any earlier attempt to shift an electron beam's phase also wrecked the beam itself. Physicist Holger Müller at UC Berkeley, building on a 2010 proposal with Robert Glaeser, spent 15 years constructing a laser intense enough to do the job instead — 75 kilowatts of continuous power focused down to a few microns and bounced through a mirrored chamber more than 10,000 times to build up intensity, strong enough to shift the electron beam's phase without damaging the beam itself. In early tests, the resulting "laser phase plate" sharpened images of hemoglobin and other proteins so small they sit right at the edge of what cryo-EM can normally detect, and the team's longer-term goal is imaging proteins about a third that size, a class that covers roughly 90% of all human proteins.
ScienceDaily, reporting Holger Müller, Robert M. Glaeser et al., UC Berkeley / Biohub / Science · Oct 22, 2026 · sciencedaily.com
§
Why it's hereCryo-EM already won a Nobel for transforming how scientists see proteins, and watching a second, even older Nobel-winning idea get successfully bolted onto it is a good reminder that big scientific instruments often advance by combining old tricks in new ways, not just inventing brand-new ones.
A spider small enough to perch on a coin twitches its legs and moves its eyes during sleep, in patterns that look eerily like the dreaming stage of human sleep.
Portia fimbriata is an Australian jumping spider about the size of a one-euro coin, known among biologists for hunting other spiders by faking the vibrations of a trapped insect to lure its prey close. Researchers at the University of Bonn, led by Daniela Rößler and Nadja Geiger, wanted to know whether an animal with a nervous system this different from ours — spiders have nothing resembling a human-style brain — actually sleeps the way vertebrates do, or just goes still. Filming the spiders overnight with infrared cameras in small dishes, they found two distinct sleep stages, and one of them looked strikingly familiar: the spiders' eyes moved and their legs twitched, echoes of the rapid-eye-movement (REM) stage associated with dreaming in humans and other vertebrates. To confirm the spiders were genuinely asleep rather than just sitting still, the team measured how quickly they reacted to sounds and also deprived them of sleep to see whether they'd "catch up" on it afterward; both tests came back consistent with real, regulated sleep. The researchers are careful to say twitching legs and moving eyes don't prove a spider dreams — they measured behavior only, not brain activity — but finding REM-like sleep in an animal this far from us raises real questions about how early in evolution these sleep patterns first appeared.
ScienceDaily, reporting Daniela C. Rößler, Nadja Geiger et al., University of Bonn / Proceedings of the National Academy of Sciences · Oct 27, 2026 · sciencedaily.com
§
Why it's here"Do spiders dream?" sounds like a joke question until you realize nobody could actually answer it before now, and the honest answer here — real evidence, zero proof, a lot of good follow-up questions — is more interesting than a flat yes or no would have been.
No surgery, no new drug — a strict six-month diet and exercise plan sent more than half of young adults with type 2 diabetes into remission, compared to almost none on standard care.
Type 2 diabetes diagnosed in people under 45 tends to be unusually aggressive, progressing faster and causing complications earlier than when it's diagnosed later in life. A team led by Kaberi Dasgupta at McGill University and Thomas Yates at the University of Leicester tested whether a structured program — an 800-to-900-calorie-a-day diet combined with supervised exercise twice a week — could reverse it, in a randomized trial of 96 adults aged 18 to 45 with early-onset type 2 diabetes. After 24 weeks, 27 of the 50 people on the program, 54%, had achieved remission (blood sugar back under the diabetic threshold with no medication for at least 12 weeks), compared with just 2 of 46 people, about 4%, on standard care — making remission roughly 21 times more likely with the program. The diet group also lost an average of 8.4 kilograms more than the control group, and because the program paired calorie restriction with resistance exercise, most of that was fat rather than muscle, which matters because crash diets alone tend to burn through muscle along with fat. It's a demanding program — most participants on it reported at least one side effect, like fatigue or headaches, usually in the first few weeks — and the real open question now is whether people can hold onto the weight loss and the remission once the trial ends and ordinary life resumes.
ScienceDaily, reporting Kaberi Dasgupta, Thomas Yates et al., McGill University & University of Leicester / The Lancet Regional Health – Americas · Oct 30, 2026 · sciencedaily.com
§
Why it's hereType 2 diabetes stories usually land as either doom or a miracle pill. This one is neither — it's a hard, unglamorous intervention that worked dramatically better than expected, with the honest caveat that "hard to stick to" is a real cost of its own.
The 1989 "cold fusion" announcement collapsed within months and became science's most famous cautionary tale — but a real, much stranger version of fusion at room temperature has been quietly studied since the 1950s.
In 1989, two chemists announced they'd triggered nuclear fusion in a jar at room temperature — a claim so extraordinary, and so wrong, that "cold fusion" became shorthand for junk science almost overnight once other labs couldn't reproduce it. But science writer George Musser points out, in a recent essay, that an entirely different and legitimate phenomenon also goes by "cold fusion": muon-catalyzed fusion, first observed in the 1950s, which uses a muon — a particle like an electron but about 207 times heavier — to momentarily squeeze two hydrogen nuclei close enough together to fuse. Because a heavier particle orbits closer to the nucleus it's attached to, swapping an electron for a muon shrinks an atom dramatically, and physicists at CERN and Japan's J-PARC facility, including Shinji Okada at Chubu University and Cătălina Curceanu at Italy's INFN, are now using muons and even heavier, short-lived particles to build these shrunken "exotic atoms" and study extreme physics with them, not to generate power. The catch that's kept this from ever becoming an energy source is brutal: each muon survives only about two microseconds, and to break even on energy, a single muon would need to catalyze roughly 300 fusion reactions before it decays, a number nobody has come close to reaching. Okada argues that reaching that number isn't really the point anyway — muon-catalyzed fusion could still turn out to be useful for things like producing medical isotopes, which don't need a net energy profit to be worthwhile.
Why it's hereIt's a genuinely useful lesson in how one famous failure can bury an entire legitimate field of study under its reputation — "cold fusion" sounds like a punchline, but the real research hiding behind that label is strange, serious science that deserves better than guilt by association.
Sources this issue
ScienceDaily, reporting Shantia Yarahmadian, Yasser Alzahrani & Vaghawan Prasad Ojha, Mississippi State University / Bulletin of Mathematical Biology — math
ScienceDaily, reporting Holger Müller, Robert M. Glaeser et al., UC Berkeley / Biohub / Science — chemistry
ScienceDaily, reporting Daniela C. Rößler, Nadja Geiger et al., University of Bonn / Proceedings of the National Academy of Sciences — biology
ScienceDaily, reporting Kaberi Dasgupta, Thomas Yates et al., McGill University & University of Leicester / The Lancet Regional Health – Americas — medicine